AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26890974 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (COF)
Number of subjects: 9
Study 26890974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 26890974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhydrous caffeine (CAF)
Number of subjects: 9
Study 26890974 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (DEC)
Number of subjects: 9
Study 26396949 — intervention group
Group type: EXPERIMENTAL
Intervention: Narivent(®)
Number of subjects: 40
Study 26396949 — intervention group
Group type: COMPARATOR
Intervention: Topical intranasal corticosteroid
Number of subjects: 40
Study 22951921 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched-bias (MB) exercises
Number of subjects: 33
Study 22951921 — intervention group
Group type: COMPARATOR
Intervention: Unmatched-bias (UB) exercises
Number of subjects: 33
Study 20577273 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard‐fluence verteporfin photodynamic therapy (PDT) + ranibizumab
Number of subjects: 18
Study 20577273 — intervention group
Group type: COMPARATOR
Intervention: Sham (control) + ranibizumab
Number of subjects: 18
Study 20577273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PDT and sham)
Number of subjects: 18
Study 20577273 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT group
Number of subjects: 18
Study 20577273 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 18
Study 17472600 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenica R
Number of subjects: 24
Study 17472600 — intervention group
Group type: COMPARATOR
Intervention: Depakene R
Number of subjects: 24
Study 15704509 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training with additional physical therapy
Number of subjects: 54
Study 15704509 — intervention group
Group type: COMPARATOR
Intervention: Home training without additional physical therapy
Number of subjects: 54
Study 12100642 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V (visual stimuli) - soundless video display of natural scenery during tourniquet inflation
Number of subjects: 46
Study 12100642 — intervention group
Group type: COMPARATOR
Intervention: Group B (control) - static blank screen during tourniquet inflation
Number of subjects: 46
Study 10546865 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital Ulcer Disease (GUD)
Number of subjects: 8089
Study 10546865 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge/Dysuria in males
Number of subjects: 8089
Study 10546865 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the three STD symptoms
Number of subjects: 8089
Study 10546865 — intervention group
Group type: EXPERIMENTAL
Intervention: GUD
Number of subjects: 8089
Study 10546865 — intervention group
Group type: EXPERIMENTAL
Intervention: STD symptoms in HIV-positive persons
Number of subjects: 8089
Study 9060344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program; Details: Not specified
Number of subjects: 0
Study 9060344 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group education
Number of subjects: 0
Study 9060344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program with examples of safety devices
Number of subjects: 0
Study 2005707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 154
Study 2005707 — intervention group
Group type: COMPARATOR
Intervention: Propantheline
Number of subjects: 154
Study 2005707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 6386033 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide treatment (400 micrograms ZnO/cm2)
Number of subjects: 37
Study 6386033 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (identical compress without zinc oxide)
Number of subjects: 37
Study 30542749 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration sclerotherapy
Number of subjects: 32
Study 30542749 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 29610765 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implant (modified design intended to increase primary stability)
Number of subjects: 33
Study 29610765 — intervention group
Group type: COMPARATOR
Intervention: Control implant (standard design)
Number of subjects: 33
Study 29610765 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control implants
Number of subjects: 33
Study 26854741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) training
Number of subjects: 60
Study 26854741 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice (PP) training
Number of subjects: 60
Study 26854741 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous work)
Number of subjects: 60
Study 25482871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 150 mg
Number of subjects: 0
Study 25482871 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 0
Study 25482871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22740508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX3) levels measured at randomization and after 3 months
Number of subjects: 2680
Study 22740508 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 2680
Study 20435966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy
Number of subjects: 104
Study 20435966 — intervention group
Group type: COMPARATOR
Intervention: Treatment by experienced community psychotherapists
Number of subjects: 104
Study 18378545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (30 g/day)
Number of subjects: 52
Study 18378545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 52
Study 16167225 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastric anastomosis with mucosal valve (Group A, 175 cases)
Number of subjects: 464
Study 16167225 — intervention group
Group type: COMPARATOR
Intervention: Mechanical stapler (Group B, 151 cases)
Number of subjects: 464
Study 16167225 — intervention group
Group type: COMPARATOR
Intervention: One layer anastomosis with handcraft suture (Group C, 138 cases)
Number of subjects: 464
Study 12435654 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical orthoses with army boots
Number of subjects: 9
Study 12435654 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft biomechanical orthoses with army boots
Number of subjects: 9
Study 12435654 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid biomechanical orthoses with army boots
Number of subjects: 9
Study 12435654 — intervention group
Group type: COMPARATOR
Intervention: Biomechanical orthoses with running shoes
Number of subjects: 9
Study 10551383 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 78
Study 10551383 — intervention group
Group type: EXPERIMENTAL
Intervention: Disappearance of HCV RNA from serum at week 4
Number of subjects: 78
Study 10551383 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta sIL-2R
Number of subjects: 78
Study 10551383 — intervention group
Group type: EXPERIMENTAL
Intervention: Disappearance of HCV RNA and delta sIL-2R
Number of subjects: 78
Study 7599241 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic rehabilitation
Number of subjects: 371
Study 7599241 — intervention group
Group type: COMPARATOR
Intervention: Geriatric rehabilitation
Number of subjects: 371
Study 2217831 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-PGI2 (2 micrograms daily for one week)
Number of subjects: 17
Study 2217831 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 2217831 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-PGI2
Number of subjects: 17
Study 649242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid
Number of subjects: 19
Study 649242 — intervention group
Group type: EXPERIMENTAL
Intervention: Noramidopyrinium methane sulfonate sodium
Number of subjects: 19
Study 649242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocin
Number of subjects: 19
Study 649242 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate
Number of subjects: 19
Study 649242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31434813 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreliable information sources (Internet, TV, radio, word of mouth)
Number of subjects: 2130
Study 31434813 — intervention group
Group type: COMPARATOR
Intervention: Reliable information sources (municipal public relations, major media)
Number of subjects: 2130
Study 28727231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 72
Study 28727231 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of nulliparous women
Number of subjects: 72
Study 24471418 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation condition
Number of subjects: 125
Study 24471418 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 125
Study 23508376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using green 532 nm diodes
Number of subjects: 68
Study 23508376 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 68
Study 23508376 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 68
Study 21634310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness for Life (FFL) program
Number of subjects: 156
Study 21634310 — intervention group
Group type: COMPARATOR
Intervention: Traditional high-intensity fitness (TRAD) program
Number of subjects: 156
Study 19621732 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug Hp eradication therapy (lansoprazole 30 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid) for 2 weeks
Number of subjects: 44
Study 17060216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivariate log-normal survival models
Number of subjects: 0
Study 17060216 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat randomization
Number of subjects: 0
Study 17060216 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study approach
Number of subjects: 0
Study 15580808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification (consuming one additional citrus fruit after lunch)
Number of subjects: 62
Study 15580808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education (teaching the mothers proper eating patterns based on the food pyramid)
Number of subjects: 62
Study 15580808 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study 11368983 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg administered twice immediately before ovulation
Number of subjects: 12
Study 9412549 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (800 micrograms/day)
Number of subjects: 10
Study 9412549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7528360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (30,000 KIU/kg in the priming solution)
Number of subjects: 30
Study 7528360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 30
Study 3293777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplements (400 mg each of ascorbic acid and alpha-tocopherol)
Number of subjects: 200
Study 3293777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3293777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 200
Study 31804028 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG (1064 nm) laser
Number of subjects: 20
Study 31804028 — intervention group
Group type: COMPARATOR
Intervention: Q-Switched Nd:YAG (1064 nm) laser
Number of subjects: 20
Study 31253213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 80
Study 31253213 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 80
Study 29072165 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care therapy for respiratory infection along with a single oral dose of 100,000 IU of vitamin D3
Number of subjects: 154
Study 29072165 — intervention group
Group type: COMPARATOR
Intervention: Standard care therapy alone
Number of subjects: 154
Study 29130267 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN) intervention with hospital visits and telephone outreach for 30 days post-discharge
Number of subjects: 0
Study 29130267 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 29130267 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort (Control)
Number of subjects: 0
Study 24076011 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month home-based physical activity (PA) intervention
Number of subjects: 170
Study 24076011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 20828714 — intervention group
Group type: EXPERIMENTAL
Intervention: New hypotonic ORS containing zinc and prebiotics (group 2)
Number of subjects: 119
Study 20828714 — intervention group
Group type: COMPARATOR
Intervention: Standard hypotonic ORS (group 1)
Number of subjects: 119
Study 19737278 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-selective intraprostatic androgen deprivation therapy
Number of subjects: 6
Study 17175104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 119
Study 17175104 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib (selective COX-2 inhibitor)
Number of subjects: 119
Study 17175104 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac (dual COX-1/COX-2 inhibitor)
Number of subjects: 119
Study 17175104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 14996144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for up to 8 weeks
Number of subjects: 37
Study 11977360 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment
Number of subjects: 28
Study 11977360 — intervention group
Group type: COMPARATOR
Intervention: Control group (22 healthy controls)
Number of subjects: 28
Study 9046143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal approach
Number of subjects: 52
Study 9046143 — intervention group
Group type: COMPARATOR
Intervention: Plantar approach
Number of subjects: 52
Study 7935234 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with midazolam and fentanyl
Number of subjects: 13
Study 7935234 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anesthesia with thiamylal, enflurane, and nitrous oxide
Number of subjects: 13
Study 3341258 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat acidified milk fortified with 15 mg of elemental Fe as ferrous sulfate and 100 mg of ascorbic acid/100 g of powder
Number of subjects: 276
Study 3341258 — intervention group
Group type: COMPARATOR
Intervention: Control group (milk without additives)
Number of subjects: 276
Study 30379086 — intervention group
Group type: EXPERIMENTAL
Intervention: %predicted SVC
Number of subjects: 453
Study 30379086 — intervention group
Group type: COMPARATOR
Intervention: Baseline SVC < median
Number of subjects: 453
Study 30379086 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller declines in SVC over time
Number of subjects: 453
Study 28025964 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of pregabalin 150-mg capsules
Number of subjects: 0
Study 28025964 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of pregabalin 150-mg capsules
Number of subjects: 0
Study 24709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b plus ribavirin
Number of subjects: 70
Study 24709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a plus ribavirin
Number of subjects: 70
Study 24709775 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 70
Study 24709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete early virological response (cEVR)
Number of subjects: 70
Study 24709775 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low TLR3 expressing CD14+ monocytes at baseline
Number of subjects: 70
Study 23080548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential clomiphene citrate/hMG regimen (CC/hMG)
Number of subjects: 90
Study 23080548 — intervention group
Group type: COMPARATOR
Intervention: hMG regimen
Number of subjects: 90
Study 20798427 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofeedback-based teletreatment service
Number of subjects: 65
Study 20798427 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (Control)
Number of subjects: 65
Study 19271419 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCl2 5% solution (450 mg elemental magnesium)
Number of subjects: 23
Study 19271419 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 50 mg daily
Number of subjects: 23
Study 16649861 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem individuals
Number of subjects: 7
Study 16649861 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem individuals
Number of subjects: 7
Study 16649861 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-esteem
Number of subjects: 7
Study 16649861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiously attached individuals
Number of subjects: 7
Study 14602761 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 25 microg/kg.d
Number of subjects: 64
Study 14602761 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 12.5 microg/kg.d
Number of subjects: 64
Study 14602761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10744147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction rule with a score < or =4.0 and negative SimpliRED D-Dimer result
Number of subjects: 0
Study 10744147 — intervention group
Group type: EXPERIMENTAL
Intervention: Score <2.0 and negative D-Dimer
Number of subjects: 0
Study 10744147 — intervention group
Group type: EXPERIMENTAL
Intervention: Score < or =4.0
Number of subjects: 0
Study 8931521 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS)
Number of subjects: 24
Study 8123920 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ECMO
Number of subjects: 41
Study 8123920 — intervention group
Group type: COMPARATOR
Intervention: Control (continued medical management)
Number of subjects: 41
Study 3426184 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 6 MU/day
Number of subjects: 55
Study 3426184 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 3 MU/day
Number of subjects: 55
Study 3426184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 29132879 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg orally twice a day) plus Aspirin (100 mg once a day)
Number of subjects: 24824
Study 29132879 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5 mg orally twice a day)
Number of subjects: 24824
Study 25845277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg IV bolus at induction, followed by 0.25 mg/kg/h infusion until end of surgery)
Number of subjects: 52
Study 25845277 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 52
Study 24117389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 545
Study 24117389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 545
Study 24117389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially) then Ustekinumab 45 mg or 90 mg
Number of subjects: 545
Study 23561840 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose propofol (3.2 μg/mL)
Number of subjects: 42
Study 23561840 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose propofol (2.4 μg/mL)
Number of subjects: 42
Study 23561840 — intervention group
Group type: COMPARATOR
Intervention: Low-dose propofol (1.8 μg/mL)
Number of subjects: 42
Study 19092348 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac axis infusion (CAI) and radiotherapy (RT) consisting of intra-arterial mitoxantrone, 5-FU, leucovorin, and cisplatinum in combination with 30 x 1.8 Gy radiotherapy (group A)
Number of subjects: 120
Study 19092348 — intervention group
Group type: COMPARATOR
Intervention: Observation (group B)
Number of subjects: 120
Study 19092348 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac axis infusion (CAI) and radiotherapy (RT) for periampullary tumors
Number of subjects: 120
Study 19092348 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac axis infusion (CAI) and radiotherapy (RT) for pancreatic cancer
Number of subjects: 120
Study 16674623 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq Laryngoscope
Number of subjects: 25
Study 16674623 — intervention group
Group type: COMPARATOR
Intervention: Macintosh Laryngoscope
Number of subjects: 25
Study 12500073 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 or 40 mg)
Number of subjects: 121
Study 12500073 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (75 or 150 mg)
Number of subjects: 121
Study 11303310 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of trometamol (TRIS, pH = 10.5) intravenously for 5 minutes, followed by deep breathing for 5 minutes at a rate of 40/min.
Number of subjects: 76
Study 11303310 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 76
Study 8623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.06 mg.kg‐1
Number of subjects: 87
Study 8623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1
Number of subjects: 87
Study 8623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrylcholinesterase (25 ml.kg‐1 and 70 ml.kg‐1 of human plasma equivalent)
Number of subjects: 87
Study 8623998 — intervention group
Group type: COMPARATOR
Intervention: Control-TOF (group 1)
Number of subjects: 87
Study 8623998 — intervention group
Group type: COMPARATOR
Intervention: Control-PTC (group 2)
Number of subjects: 87
Study 1308025 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractometric method
Number of subjects: 102
Study 1308025 — intervention group
Group type: COMPARATOR
Intervention: Sulphosalycilic acid method
Number of subjects: 102